Iovance Biotherapeutics Bolsters Commercial Team with Appointment of Dan Kirby as Chief Commercial Officer

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial-stage biotechnology company specializing in innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, has appointed Dan Kirby as its new Chief Commercial Officer (CCO). Kirby brings extensive experience in cell therapy commercialization, having previously served as CCO at Orca Bio and Omeros, as well as holding leadership positions at Celgene (now Bristol-Myers Squibb), Juno Therapeutics, Medivation (now Pfizer), and Amgen. His appointment comes as Iovance focuses on expanding the U.S. launch of Amtagvi and growing Proleukin sales globally.



Kirby's expertise spans market access, reimbursement, marketing, and commercial strategy development for cell therapy products. His appointment is expected to significantly contribute to Iovance's growth and success, as he will play a critical role in building and leading the company's commercial team, fostering a culture of innovation and excellence, and driving the company's commercial success.

Iovance's strategic initiatives to expand the U.S. launch of Amtagvi and grow Proleukin sales globally will be supported by Kirby's appointment. Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication, while Proleukin is an interleukin-2 product aimed at treating metastatic cancers. Kirby's strengths in market engagement, reimbursement landscape evaluation, value story creation, key opinion leader outreach, communications, and advocacy will be crucial in driving these initiatives forward.

Iovance is planning regulatory submissions for Amtagvi in various markets, with potential approvals anticipated in the coming years. The company's focus on polyclonal TIL therapies differentiates it from competitors in the cell therapy landscape, presenting opportunities for future growth. By continuing to innovate in the cell therapy space and leveraging Kirby's expertise, Iovance can maintain its competitive edge and capture a larger share of the growing cell therapy market.

In conclusion, Iovance Biotherapeutics' appointment of Dan Kirby as Chief Commercial Officer is a strategic move that will significantly contribute to the company's growth and success. Kirby's extensive experience in cell therapy commercialization, combined with Iovance's focus on polyclonal TIL therapies, positions the company well to expand the U.S. launch of Amtagvi and grow Proleukin sales globally. As Iovance continues to innovate and execute on its strategic initiatives, investors can expect the company to make significant progress in the coming years.